CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers

Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.13.26368051
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers

Bernat Olle, Dmitri Bobilev, C. Lyon De Ana, Rose L. Szabady et al.
2 links
medRxiv
Cancer Immunotherapy and Biomarkers
preprint

CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers

Bernat Olle, Dmitri Bobilev, C. Lyon De Ana, Rose L. Szabady, Amanda Prince, Rajita Menon, Diwakar Davar, Jeremiah J. Faith, Vanni Bucci, Shakti K. Bhattarai, Jason M. Norman, Bruce Roberts, Scott Buresh, Erica Darrah, Jeffrey L Silber, Kenya Honda, Judy S Wang
preprint en

Abstract

Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally.

medRxiv
University of Massachusetts Chan Medical School (US), GlaxoSmithKline (United Kingdom) (GB), Veeva Systems (United States) (US), Ferring Pharmaceuticals (United States) (US), UPMC Hillman Cancer Center (US), RIKEN Center for Integrative Medical Sciences (JP), Vedantra Pharmaceuticals (United States) (US), CSL (Switzerland) (CH), Icahn School of Medicine at Mount Sinai (US)
Bristol-Myers Squibb
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon